EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real‐World Pharmacovigilance Analysis Using FAERS Data

Hepatobiliäre unerwünschte Ereignisse im Zusammenhang mit Immun-Checkpoint-Inhibitoren: Real-World-Pharmakovigilanzanalyse mit FAERS-Daten

Yuzhu Chen iD, Yixin Zeng, Kaisheng Zhang, Nand Lal, Yuxiang Zhao, Fei Qi, Tongmei Zhang

Thoracic Cancer · 2025-11 · 16 (22)

DOI: 10.1111/1759-7714.70184 ↗

Auf einen Blick

Eine FAERS-Analyse von 18 640 061 Meldungen (2004–2024) untersuchte hepatobiliäre Toxizität unter sechs ICI. PD-L1-Inhibitoren waren stärker mit immunvermittelter Leberkrankheit/Leberversagen assoziiert, PD-1-Inhibitoren eher mit Hepatitis/Leberauffälligkeiten.

Fragestellung

Wie unterscheiden sich hepatobiliäre Risiken und Zeitverläufe unter sechs PD-1/PD-L1-Inhibitoren in FAERS-Daten?

Methode

Analyse von 18 640 061 FAERS-Berichten (2004–2024) mit Disproportionalitätsanalysen (ROR, PRR, EBGM, BCPNN), Weibull-Modell und logistischer Regression.

Ergebnisse

PD-L1-Inhibitoren (Durvalumab, Atezolizumab) waren stärker mit immunvermittelter Leberkrankheit/Leberversagen assoziiert (ROR 4,28–5,07). PD-1-Inhibitoren (Nivolumab, Pembrolizumab) eher mit Hepatitis/Leberauffälligkeiten (ROR 3,42–3,93).

Schlussfolgerung der Autor:innen

Die FAERS-Analyse zeigte Unterschiede zwischen PD-L1- und PD-1-Inhibitoren bei hepatobiliären Risiken und spricht für ein wirkstoffspezifisches Monitoring.

Kernaussagen

  • PD-L1: stärkere Assoziation mit immunvermittelter Leberkrankheit/Leberversagen
  • PD-1: stärkere Assoziation mit Hepatitis/Leberauffälligkeiten
  • Medianer Beginn: 23 vs. 84 Tage je nach Wirkstoff

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 16.11.2025. Verfasst von Yuzhu Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, Chin…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) improve cancer outcomes but cause significant hepatobiliary toxicity (e.g., liver dysfunction, immune‐mediated liver disease). Prior studies were limited to small samples or case reports. This study evaluated hepatobiliary toxicity, risk variations, and temporal trends for six ICIs (PD‐1/PD‐L1 inhibitors) via the FDA Adverse Event Reporting System (FAERS) to guide safer use.

Methods

We analyzed 18 640 061 FAERS reports (2004–2024). Disproportionality analyses (ROR, PRR, EBGM, BCPNN) detected hepatobiliary toxicity signals. A Weibull model analyzed AE timing. Logistic regression assessed effects of age, gender, and weight.

Results

PD‐L1 inhibitors (Durvalumab, Atezolizumab) are associated more strongly with immune‐mediated liver disease/hepatic failure (ROR = 4.28–5.07). PD‐1 inhibitors (Nivolumab, Pembrolizumab) are linked more to hepatitis/liver abnormalities (ROR = 3.42–3.93). AE reports are common in males (53.32%) and patients > 65 years (43.43%), though demographics didn't alter risk ( p > 0.05). Median onset: 23 days (Toripalimab liver injury) vs. 84 days (Tislelizumab autoimmune hepatitis), supporting drug‐specific monitoring in the first three months.

Conclusion

Our FAERS analysis showed PD‐L1 inhibitors were more associated with immune‐mediated liver disease and hepatic failure, whereas PD‐1 inhibitors were linked to hepatitis and liver abnormalities, underscoring the need for drug‐specific monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsChemical and Drug Induced Liver InjuryNeoplasmsHumansPharmacovigilanceMaleFemaleMiddle AgedAgedUnited StatesAdult

Stichwörter der Autor:innen

FAERSdisproportionality analysisdrug‐specific riskhepatobiliary toxicityimmune checkpoint inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
  • Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
  • School of Medicine, Shaoguan University, Shaoguan, People's Republic of China.
  • Department of Physiology, Harbin Medical University, Harbin, Heilongjiang, China.
  • Department of Clinical Medicine, Fenyang College of Shanxi Medical University, Taiyuan, Shanxi, China.

ORCID-Profile: Yuzhu Chen

Förderung

  • Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes

Zitieren

APA

Chen, Y., Zeng, Y., Zhang, K., Lal, N., Zhao, Y., Qi, F., & Zhang, T. (2025). Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real‐World Pharmacovigilance Analysis Using FAERS Data. Thoracic Cancer, 16(22). https://doi.org/10.1111/1759-7714.70184

Vancouver

Chen Y, Zeng Y, Zhang K, Lal N, Zhao Y, Qi F, et al. Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real‐World Pharmacovigilance Analysis Using FAERS Data. Thoracic Cancer. 2025;16(22). doi:10.1111/1759-7714.70184

BibTeX
@article{Chen2025,
  author = {Chen, Yuzhu and Zeng, Yixin and Zhang, Kaisheng and Lal, Nand and Zhao, Yuxiang and Qi, Fei and Zhang, Tongmei},
  title = {Hepatobiliary Adverse Events Linked to Immune Checkpoint Inhibitors: A Real‐World Pharmacovigilance Analysis Using FAERS Data},
  journal = {Thoracic Cancer},
  year = {2025},
  volume = {16},
  number = {22},
  doi = {10.1111/1759-7714.70184}
}
Kostenlos starten →